EverSource Wealth Advisors LLC Has $5.40 Million Holdings in Amgen Inc. $AMGN

EverSource Wealth Advisors LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 13.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,132 shares of the medical research company’s stock after selling 2,936 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Amgen were worth $5,399,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Cary Street Partners Investment Advisory LLC grew its holdings in Amgen by 28.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 1,885 shares of the medical research company’s stock worth $532,000 after acquiring an additional 412 shares during the period. MainStreet Investment Advisors LLC boosted its position in shares of Amgen by 11.3% during the 3rd quarter. MainStreet Investment Advisors LLC now owns 1,825 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 186 shares in the last quarter. Trajan Wealth LLC boosted its position in shares of Amgen by 0.9% during the 3rd quarter. Trajan Wealth LLC now owns 16,684 shares of the medical research company’s stock valued at $4,708,000 after purchasing an additional 148 shares in the last quarter. Clearstead Advisors LLC grew its stake in Amgen by 0.4% during the third quarter. Clearstead Advisors LLC now owns 35,799 shares of the medical research company’s stock worth $10,102,000 after purchasing an additional 129 shares during the period. Finally, Equitable Trust Co. increased its holdings in Amgen by 9.7% in the third quarter. Equitable Trust Co. now owns 5,473 shares of the medical research company’s stock worth $1,544,000 after purchasing an additional 482 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $379.42 on Tuesday. The company has a market capitalization of $204.53 billion, a PE ratio of 26.66, a PEG ratio of 3.71 and a beta of 0.46. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock’s 50 day moving average price is $344.29 and its 200-day moving average price is $317.21. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s payout ratio is 70.84%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on AMGN shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Citigroup raised their price target on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Truist Financial lifted their price target on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Argus increased their price objective on shares of Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $351.76.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.